Evidence map›Paper›PMID 38244064›Full record

ArticleClinical and experimental medicine2024

Humoral responses to wild type and ancient BA.1 SARS-CoV-2 variant after heterologous priming vaccination with ChAdOx1 nCoV-19 and BNT162b2 booster dose.

Giuseppina Sanna, Alessandra Marongiu, Davide Firinu, Cristina Piras, Vanessa Palmas, Massimiliano Galdiero, Luigi Atzori, Paola Caria, Marcello Campagna, Andrea Perra and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Giuseppina SannaDepartment of Biomedical Sciences, University of Cagliari, Cittadella Universitaria, 09042, Monserrato, Cagliari, Italy. g.sanna@unica.it.ORCID http://orcid.org/0000-0002-3999-4263
Alessandra MarongiuDepartment of Biomedical Sciences, University of Cagliari, Cittadella Universitaria, 09042, Monserrato, Cagliari, Italy.
Davide FirinuDepartment of Medical Sciences and Public Health, University of Cagliari, Cittadella Universitaria, 09042, Monserrato, Cagliari, Italy. davide.firinu@unica.it.ORCID http://orcid.org/0000-0002-5768-391X
Cristina PirasClinical Metabolomics Unit, Department of Biomedical Sciences, University of Cagliari, Cittadella Universitaria, 09042, Monserrato, Cagliari, Italy.
Vanessa PalmasDepartment of Biomedical Sciences, University of Cagliari, Cittadella Universitaria, 09042, Monserrato, Cagliari, Italy.
Massimiliano GaldieroDepartment of Experimental Medicine, University of Campania Luigi Vanvitelli, 80138, Naples, Italy.
Luigi AtzoriClinical Metabolomics Unit, Department of Biomedical Sciences, University of Cagliari, Cittadella Universitaria, 09042, Monserrato, Cagliari, Italy.
Paola CariaDepartment of Biomedical Sciences, University of Cagliari, Cittadella Universitaria, 09042, Monserrato, Cagliari, Italy.
Marcello CampagnaDepartment of Medical Sciences and Public Health, University of Cagliari, Cittadella Universitaria, 09042, Monserrato, Cagliari, Italy.
Andrea PerraUnit of Oncology and Molecular Pathology, Department of Biomedical Sciences, University of Cagliari, Cittadella Universitaria, 09042, Monserrato, Cagliari, Italy.
Giulia CostanzoDepartment of Medical Sciences and Public Health, University of Cagliari, Cittadella Universitaria, 09042, Monserrato, Cagliari, Italy.
Ferdinando CogheLaboratory Clinical Chemical Analysis and Microbiology, University Hospital of Cagliari, 09042, Monserrato, Italy.
Roberto LitteraMedical Genetics, Department of Medical Sciences and Public Health, University of Cagliari, 09100, Cagliari, Italy.
Luchino ChessaDepartment of Medical Sciences and Public Health, University of Cagliari, Cittadella Universitaria, 09042, Monserrato, Cagliari, Italy.
Aldo ManzinDepartment of Biomedical Sciences, University of Cagliari, Cittadella Universitaria, 09042, Monserrato, Cagliari, Italy.
University of Cagliari · ITUniversity of Campania "Luigi Vanvitelli" · IT

Funding

Fondazione di Sardegna #2020.2197NextGeneration EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases PE00000007, INF-ACT
6 · The paper itself

Abstract

Several countries have recommended a booster dose of Pfizer BNT162b2 vaccine for subjects under the age of 60, who have already received the first dose of ChAdOx1. This is due to several ChAdOx1 vaccine-associated adverse vascular events and thrombocytopenia. Neutralization assay and quantitative IgG anti-SARS-CoV-2 Spike antibody (anti-S-IgG) were conducted to investigate the long-term responses to vaccine treatment in a cohort of Sardinian participants, who have received heterologous Prime-Boost Vaccination via ChAdOx1 vector vaccine and a booster dose via BNT162b2. The obtained results were compared with those of a cohort of healthcare workers (HCW) who received homologous BNT162b2 (BNT/BNT/BNT) vaccination. One month (T2) and five months after the second and before the third dose (T3), anti-spike antibody or neutralizing titers in the subjects vaccinated with ChAdOx1-S/BNT162b2 were significantly higher than those who experienced the ChAdOx1-S/ChAdOx1-S or BNT162b2/BNT162b2 schedule. These results suggest that a ChAdOx1-S/BNT162b2 regimen provides a more robust antibody response than either of the homologous regimens. However, the anti-spike antibodies or neutralizing titers after the third injection (mRNA vaccine) of ChAdOx1-S as a second dose and BNT162b2 were not statistically different. Homologous and heterologous vaccination provided a strong antibody response. Neutralizing activities were also described against the Omicron BA.1 variant in a sub-group (40) representative of the three vaccination regimens among our cohort.

Indexed as

BNT162 VaccineCOVID-19Antibodies, ViralChAdOx1 nCoV-19HumansImmunoglobulin GSARS-CoV-2VaccinationAntibodies, ViralBNT162 VaccineChAdOx1 nCoV-19Immunoglobulin GAnti-S-IgGBNT162b2 vaccineBoosterChAdOx1-S vaccineCOVID-19Neutralizing antibodiesOmicron BA.1

Identifiers

PMID38244064
PMCPMC10799790
OpenAlexW4391051973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.